Neurocrine Biosciences (NBIX) Treasury Shares (2010 - 2025)
Neurocrine Biosciences (NBIX) posted Treasury Shares of $2.6 million for Q4 2025, up 8.33% on a QoQ basis from $2.4 million in Q4 2024, and up 8.33% year-over-year from $2.4 million in Q4 2024.
Neurocrine Biosciences (NBIX) Treasury Shares (2010 - 2025) Analysis & Trends
Neurocrine Biosciences' Treasury Shares history runs 15 years deep, the most recent figure standing at $2.6 million for Q4 2025.
- Quarterly Treasury Shares rose 8.33% year-over-year to $2.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.6 million (up 8.33% YoY) and the FY2025 annual result came in at $2.6 million, up 8.33% from the prior year.
- Treasury Shares was $2.6 million for Q4 2025 at Neurocrine Biosciences, up from $2.4 million in the prior quarter.
- Across five years, Treasury Shares topped out at $2.6 million in Q4 2025 and bottomed at $300000.0 in Q4 2023.
- A 5-year average of $1.6 million and a median of $2.0 million in 2021 frame the typical range for Treasury Shares.
- Annual changes were most pronounced in 2022 — Treasury Shares plunged 75.0% — and 2024, when it jumped 700.0%.
- Neurocrine Biosciences' Treasury Shares stood at $2.0 million in 2021, then plunged by 75.0% to $500000.0 in 2022, then tumbled by 40.0% to $300000.0 in 2023, then soared by 700.0% to $2.4 million in 2024, then increased by 8.33% to $2.6 million in 2025.
- Business Quant data shows NBIX's Treasury Shares at $2.6 million in Q4 2025, $2.4 million in Q4 2024, and $300000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 62.52 Mn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 107.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.29 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 313.27 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.44 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.01 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 59.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.60 Mn |
| Dec 31, 2025 | 2.60 Mn |
| Dec 31, 2024 | 2.40 Mn |
| Dec 31, 2024 | 2.40 Mn |
| Dec 31, 2023 | 300,000.00 |
| Dec 31, 2023 | 300,000.00 |
| Dec 31, 2022 | 500,000.00 |
| Dec 31, 2022 | 500,000.00 |
| Dec 31, 2021 | 2.00 Mn |
| Dec 31, 2021 | 2.00 Mn |
| Dec 31, 2020 | 1.50 Mn |
| Dec 31, 2020 | 1.50 Mn |
| Dec 31, 2019 | 1.40 Mn |
| Dec 31, 2019 | 1.40 Mn |
| Dec 31, 2018 | 300,000.00 |
| Dec 31, 2018 | 300,000.00 |
| Sep 30, 2018 | 300,000.00 |
| Sep 30, 2018 | 300,000.00 |
| Jun 30, 2018 | 300,000.00 |
| Jun 30, 2018 | 300,000.00 |